OABI
OmniAb·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OABI
Omniab, Inc.
A biotech company that develops and commercializes novel antibody therapeutics
5980 Horton Street, Suite 600 , Emeryville, CA 94608
--
OmniAb, Inc., was incorporated on December 14, 2015 under the laws of the State of Delaware. OmniAb's discovery platform provides pharmaceutical industry partners with access to a variety of antibody libraries and high-throughput screening technologies to enable the discovery of next-generation therapies. At the core of the OmniAb platform is their proprietary Biological Intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which are genetically modified to produce antibodies with human sequences to facilitate the development of therapeutic drug candidates in humans. OmniFlic (transgenic rats) and OmniClic (transgenic chickens) meet the industry's need for bispecific antibody applications through a common light chain method, while OmniTaur has the unique structural properties of bovine antibodies against complex targets. Established core competencies focused on ion channels and transport aircraft further differentiate their technologies and create opportunities in emerging target categories. OmniAb antibodies have been used in a variety of modes, including bispecific antibodies, antibody-drug conjugates, and more. The OmniAb technology suite spans from BI-driven library generation to cutting-edge antibody discovery and optimization, providing an efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
Earnings Call
Q1/2025
Estimate EPS-0.17
Actual EPS-0.17
Estimate Revenue4.49M
Actual Revenue4.15M
Contradictory Insights from OmniAb's Q1 2025 Earnings Call: Tariffs, FDA Impacts, and Revenue Strategies
May 19,2025 05:24
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.15
Actual EPS-0.15
Estimate Revenue5.33M
Actual Revenue3.90M
OmniAb's Q2 2025 Earnings Call: Navigating Contradictions in xPloration Revenue and Partner Trends
Aug 11,2025 09:50
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.14
Actual EPS-0.14
Estimate Revenue5.64M
Actual Revenue2.24M
OmniAb's Q3 2025: Contradictions Emerge on xPloration Revenue Timing, Partner Access, and OmniUltra Partnership Potential
Nov 04,2025 11:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
OABI has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.14, meeting expectations. The chart below visualizes how OABI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OABI has released its 2025 Q3 earnings report, with revenue of 2.24M, reflecting a YoY change of -46.33%, and net profit of -16.52M, showing a YoY change of -0.93%. The Sankey diagram below clearly presents OABI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
